Co-Diagnostics (CODX) Releases Earnings Results, Misses Estimates By $0.01 EPS

Co-Diagnostics (NASDAQ:CODX) issued its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01), MarketWatch Earnings reports.

Co-Diagnostics stock traded down $0.16 during mid-day trading on Thursday, hitting $0.93. The company had a trading volume of 27,055 shares, compared to its average volume of 685,462. Co-Diagnostics has a 1 year low of $0.90 and a 1 year high of $6.66.

Several brokerages recently weighed in on CODX. HC Wainwright began coverage on shares of Co-Diagnostics in a report on Monday, March 11th. They issued a “buy” rating and a $2.00 target price on the stock. Maxim Group began coverage on shares of Co-Diagnostics in a report on Tuesday, April 9th. They issued a “buy” rating and a $2.00 target price on the stock.

WARNING: “Co-Diagnostics (CODX) Releases Earnings Results, Misses Estimates By $0.01 EPS” was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://dakotafinancialnews.com/2019/05/16/co-diagnostics-codx-releases-earnings-results-misses-estimates-by-0-01-eps.html.



Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc was founded in 2013 and is headquartered in Salt Lake City, Utah.

See Also: What is the CBOE Russell 2000® Volatility Index?

Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.